10 Oversold Value Stocks To Buy
In this piece, we will take a look at ten oversold value stocks to buy. If you want to skip an introduction to value investing and oversold stocks, then take a look at 5 Oversold Value Stocks To Buy. ...
- Supported exchanges /
- NASDAQ /
- APVO.NASDAQ
Aptevo Therapeutics Inc (APVO NASDAQ) stock market data APIs
$0.3
-0.05(-14.1%)
as of October 22, 2024
Price chart is built with Anychart
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Aptevo Therapeutics Inc Financial Data Overview
| 0.3536 | |
| 0.3 | |
| - | |
| 0.515 | |
| 0.2773 | |
| 0.138-15.1446 | |
| 4 753 K | |
| 13 441 K | |
| 0 | |
| -1.67 | |
| 5.146 |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'APVO',
Type:
'Common Stock',
Name:
'Aptevo Therapeutics Inc',
Exchange:
'NASDAQ',
CurrencyCode:
'USD',
CurrencyName:
'US Dollar',
CurrencySymbol:
'$',
CountryName:
'USA',
CountryISO:
'US',
OpenFigi:
'BBG009RRZ8C2',
ISIN:
NULL,
CUSIP:
NULL,
CIK:
'1671584',
EmployerIdNumber:
'81-1567056',
FiscalYearEnd:
'December',
IPODate:
'2016-07-20',
InternationalDomestic:
'Domestic',
Sector:
'Healthcare',
Industry:
'Biotechnology',
HomeCategory:
'Domestic',
IsDelisted:
false,
}
Aptevo Therapeutics Inc Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -25 515 000
- Earnings Per Share -35.64
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Aptevo Therapeutics Inc Earnings via APIs
- Latest Release 2024-08-08
- EPS/Forecast -6.55
Get Aptevo Therapeutics Inc End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get Aptevo Therapeutics Inc latest news via APIs
Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering
SEATTLE, WA / ACCESSWIRE / August 4, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical stage biotechnology company focused on developing novel immuno-oncology thera...
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
